Chimeric Antigen Receptor T Cell

Engineering a patient’s T cells to recognize certain tumor antigens to incite an immune response

Cellular therapies that utilize patients’ own (autologous) T cells are an example of truly personalized cancer therapy. In this experimental approach, autologous engineered T cells that express a Chimeric Antigen Receptor (CAR) specific for a defined cancer-associated antigen are amplified in a highly-controlled laboratory and later administered back to the patient.1‑4 Through modification of the CAR vector to target selected novel cancer antigens, future CAR T cell therapies may potentially be applied to a wide array of hematological and solid tumor indications.4

References
close
  1. Kochenderfer JN, et al. J Clin Oncol. 2015;33:540-549.
  2. Ramos CA, et al. Annu Rev Med. 2016;67:165-183.
  3. Lee DW, et al. Lancet. 2015;385:517-528.
  4. Davila ML, et al. Cancer J. 2015;21:470-474.